ARS Pharmaceuticals Inc. (SPRY)

NasdaqGM: SPRY · 실시간 가격 · USD

6.10

+0.05 (0.83%)

종가 기준: Aug 13, 2026, 3:59 PM

5.18

-15.06%

프리마켓: 7:18 AM

0.83% (1D)

매수호가	3.89
시가총액	605.75M
매출 (ttm)	98.99M
순이익 (ttm)	-197.98M
베타	0.97
EPS (ttm)	-2.01
P/E (ttm)	n/a
선행 P/E	-7.72
P/B (ttm)	9.89
P/S (ttm)	6.12
Earnings Date	Aug 13, 2026

매도호가	6.72
거래량	1,944,858
평균 거래량 (20일)	2,028,222
시가	6.12
전일 종가	6.05
일중 범위	5.90 - 6.19
52주 범위	4.91 - 15.09
애널리스트	n/a
목표주가	27 (342.62%)
배당	n/a
배당락일	n/a

SPRY 소개

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 4, 2020

직원 수 154

상장 거래소 NasdaqGM

티커 SPRY

웹사이트 https://ars-pharma.com

전체 기업 정보

재무 실적

2025년 ARS Pharmaceuticals의 매출은 84.28M로, 전년 89.15M 대비 -5.46% 감소했습니다. 순이익은 -171.3M로, -2,241.76% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 4명의 투자의견을 종합하면 SPRY 주식의 평균 등급은 "null"입니다. 12개월 목표주가는 27로, 최근 주가 대비 342.62% 상승 여력입니다.

주가 전망

어닝 서프라이즈

신규

ARS Pharmaceuticals가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $22.68M 예상치 하회 $0, 및 184.47% 전년 대비 성장.

EPS -0.63 예상치 하회 -0.14, 및 -36.96% 전년 대비 감소.

뉴스

2시간 전 · GuruFocus.com

ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...

CEO Donn Casale outlines path to cash flow breakeven by 2027 while navigating slower-than-expected adoption and manufacturing headwinds.

4시간 전 · MarketBeat

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused ...

10시간 전 · Zacks

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

1주 전 · Zacks

Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

4주 전 · Insider Monkey

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the...

2 페이지 중 1

ARS Pharmaceuticals Inc. (SPRY)

SPRY 소개

재무 실적